Development of Opioid and Adjuvant Fixed Combination Dosage Forms for the Treatment of Chronic Pain with Reduced Addiction Potential (R43/R44)
|Incentive Type:||Grant Program|
|Governing Body:||National Institutes of Health|
|What’s it worth?:||Not mentioned|
This is a Small Business Innovation Technology Transfer Research (STTR) grant opportunity (PA-13-387) for small business concerns (SBCs), with no more than 500 employees, to develop opioid and adjuvant single-dose treatments that enhance pain management and reduce risk of opioid addiction or other side-effects.
Maximum funding is generally $150,000 for Phase 1 of the research project and $1,000,000 for Phase 2, with the potential for 50% more (up to $225,000 in Phase 1 and $1,500,000 in Phase 2) or even higher if the additional funding is determined to be justified or necessary.